Patents by Inventor Michael E. Burczynski

Michael E. Burczynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SRC ACTIVATION FOR DETERMINING CANCER PROGNOSIS AND AS A TARGET FOR CANCER THERAPY
    Publication number: 20100081666
    Abstract: Methods of cancer diagnosis and prognosis using biomarkers.
    Type: Application
    Filed: July 14, 2009
    Publication date: April 1, 2010
    Applicant: Wyeth
    Inventors: Christina M. COUGHLIN, Michael E. BURCZYNSKI, Marisa P. DOLLED-FILHART, Robert PINARD, Donald WALDROM, Charles ZACHARCHUK, Frederick IMMERMANN, Maha KARNOUB, Jason CHRISTIANSEN, Mark GUSTAVSON, Annette MOLINARO, Alpana Waldron
  • Methods for monitoring drug activities in vivo
    Patent number: 7643943
    Abstract: Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: January 5, 2010
    Assignee: Wyeth LLC
    Inventors: Michael E. Burczynski, Joseph Boni, Andrew J. Dorner, Natalie C. Twine, Jennifer Stover, William L. Trepicchio, Virginia Fitzpatrick, Fred Immermann
  • Methods for diagnosing RCC and other solid tumors
    Patent number: 7611839
    Abstract: Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: November 3, 2009
    Assignee: Wyeth
    Inventors: Natalie C. Twine, Michael E. Burczynski, William L. Trepicchio, Andrew J. Dorner, Jennifer A. Stover, Donna K. Slonim
  • NESTED PCR-BASED METHOD FOR SPECIFIC GENOTYPING OF THE FC GAMMA RECEPTOR IIIA GENE
    Publication number: 20090142763
    Abstract: The application describes a novel method for detection of a single nucleotide polymorphism, e.g., the 158 F/V polymorphism, in the Fc?RIIIa gene using nested PCR to amplify large gene amplicons to aid in, e.g., genotyping applications. Thus, based on the results obtained in Fc?RIIIa genotyping analysis, the present invention provides specific, efficient, reproducible, and accurate detection of such polymorphisms in genomic DNA.
    Type: Application
    Filed: August 22, 2008
    Publication date: June 4, 2009
    Applicant: Wyeth
    Inventors: Michael E. BURCZYNSKI, Jennifer A. Isler, Anna M. Slager, Wenyan Zhong
  • Methods for monitoring drug activities in vivo
    Publication number: 20040235020
    Abstract: Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulateable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.
    Type: Application
    Filed: March 5, 2004
    Publication date: November 25, 2004
    Inventors: Michael E. Burczynski, Joseph Boni, Andrew J. Dorner, Natalie C. Twine, Jennifer Stover, William L. Trepicchio, Virginia Fitzpatrick, Fred Immerman
  • Methods for monitoring drug activities in vivo
    Publication number: 20040175743
    Abstract: Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells can be modulated by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for monitoring drug activities in vivo.
    Type: Application
    Filed: February 11, 2004
    Publication date: September 9, 2004
    Inventors: Michael E. Burczynski, Natalie C. Twine, Andrew J. Dorner, William L. Trepicchio
  • Methods for diagnosing RCC and other solid tumors
    Publication number: 20040110221
    Abstract: Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 10, 2004
    Applicant: Wyeth
    Inventors: Natalie C. Twine, Michael E. Burczynski, William L. Trepicchio, Andrew J. Dorner, Jennifer A. Stover, Donna K. Slonim